Oxford BioDynamics shares gain on Covid test publication, advancing Long Covid and Chronic Fatigue Syndrome research

Sly Saint

Sly Saint

Senior Member (Voting Rights)
Oxford BioDynamics(OBD) , a biotechnology company developing precision medicine tests, said its prognostic Covid Severity Test (CST) has been presented in a peer-reviewed paper published in the European Society of Medicine, with extended analysis into the related conditions of Long Covid and Chronic Fatigue Syndrome.

The test makes predictions based on a 6-marker model. In the published study, it demonstrated a high positive predictive value for high-risk disease outcomes in the validation cohort. Within the validation cohort, two patients declared clinically to be mild cases were identified as high risk by the test and subsequently died within 28 days of admission.

The results suggest an early, pre-symptomatic detection by the biomarkers of a hyperinflammatory state leading to fatal outcomes. The test for high-risk disease outcome demonstrated a positive predictive value (PPV) of 92.9%, 88% sensitivity, 87% specificity, and a balanced accuracy of 87.9% for all 116 patients used in the study.

Moreover,

OBD
noted that its EpiSwitch database, on which the test is based, was useful in identifying genes associated with patients suffering from Long Covid and other fatigue conditions such as Chronic Fatigue Syndrome (CFS) and Myalgic Encephalomyelitis (ME), for which the largest risk of onset is associated with infectious diseases.



View from Vox
Oxford BioDynamics shares surge 13% in early Friday trade, as the company announces the publication of a paper in a peer-reviewed journal detailing the effectiveness of its EpiSwitch platform-based Covid Severity Test (CST), with related insight linking it to Long Covid and CFS/ME. The platform has already delivered commercial tests and reliable biomarkers for immuno-oncology (CiRT) and prostate cancer (PSE), now adding Covid and fatigue-related conditions to the list.

Investors have more to look forward to, as the London School of Hygiene and Tropical Medicine, Norwich Medical School, and University of East Anglia, have now agreed to grant OBD access to a biobank of samples from CFS/ME patients for direct analysis and identification of diagnostic and prognostic blood biomarkers.
Click to expand...
Oxford BioDynamics shares gain on Covid test publication, advancing Long Covid and Chronic Fatigue Syndrome research - Vox Markets

(sorry I have looked for the research this is referring to)
 
I think this is the paper they mention:

Development and evaluation of blood-based prognostic biomarkers for COVID disease outcomes using EpiSwitch 3-dimensional genomic regulatory immuno-genetic profiling, 2024, Hunter et al

Using the 3D genomics knowledgebase, with >1 billion 3D genomic datapoints derived from clinical studies, a subset of 77 of the acute COVID-associated prognostic 3D biomarkers were found close to 10 loci genetically linked to fatigue-dominant PCS, and to be informative biomarkers in 6 diseases with fatigue as a symptom.
Click to expand...
 
InitialConditions said:
View attachment 23893 View attachment 23894
Click to expand...
Oxford BioDynamics shares surge 13% in early Friday trade, as the company announces the publication of a paper in a peer-reviewed journal detailing the effectiveness of its EpiSwitch platform-based Covid Severity Test (CST), with related insight linking it to Long Covid and CFS/ME.
Click to expand...
Zooming in more, nothing special happened this morning. The stock went up from yesterday, but still lower than two days ago. And the paper above, if it's the right one, was published in September, so I don't know why it would make the stock surge today.

Screenshot_20241025-151250.png
 
You must log in or register to reply here.
Back
Top Bottom